drugset / Trial / NCT01143259
Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use
Completed
274 enrolled
Intermountain Health Care, Inc.
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine if the addition of alvimopan to our care process model for colon resection patients will decrease length of stay. The care process model is a combination of optimal IV fluid management, early feeding, early ambulation, patient education, and pain management.
Timeline
- Start
- 2010-05
- Primary completion
- 2012-06
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alvimopan | Small molecule | 12 mg | Oral |